Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers

NCT ID: NCT03629236

Last Updated: 2022-04-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-06-27
• Study Completion Date: 2021-06-24

Brief Summary

A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL for the Treatment of Chronic VLUs

Conditions

Venous Leg Ulcer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GrafixPL

Group Type: EXPERIMENTAL

GrafixPL

Intervention Type: OTHER

Debridement, GrafixPL application, dressing application, standard compression therapy

Control

Group Type: ACTIVE_COMPARATOR

Control

Intervention Type: OTHER

Debridement, dressing application, standard compression therapy

Interventions

GrafixPL

Debridement, GrafixPL application, dressing application, standard compression therapy

Intervention Type: OTHER

Control

Debridement, dressing application, standard compression therapy

Intervention Type: OTHER

Other Intervention Names

Tissue Allograft

Eligibility Criteria

Inclusion Criteria

1. 18 years or older, as of the date of screening

2. An Index Ulcer that is chronic (defined as present for > 4 weeks, but not present for more than 52 weeks at Screening Visit 1)

3. Index Ulcer is located on the leg, below the knee and above the malleoli (ulcer may be inclusive of the malleoli)

4. The Index Ulcer is between 1 cm2 and 25 cm2, inclusive, at the Screening and Baseline Visits. The longest dimension of the index ulcer cannot exceed 10 cm at the Baseline Visit.

5. The Index Ulcer has had compression therapy for > 2 weeks at Screening Visit 1

6. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule

7. Patient has adequate circulation to the foot, as documented up to 14 days prior to Screening Visit 1

8. Confirmed diagnosis of venous insufficiency, as documented up to 30 days prior to enrollment

Exclusion Criteria

1. Index Ulcer is of non-venous pathophysiology

2. Gangrene is present on any part of the affected limb

3. Patient is unable to tolerate standard compression therapy

4. Glycated hemoglobin A1c (HbA1c) level of > 14% in any patient with type 1 or type 2 diabetes mellitus, as documented up to 14 days prior to Screening Visit 1

5. Patient is receiving intravenous (IV) corticosteroids, immunosuppressive or cytotoxic agents at any time during the screening period

6. Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration

7. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)

8. Current evidence of infection at the Index Ulcer, including cellulitis and/or pus drainage from the ulcer site at the time of Screening and Baseline Visits

9. Evidence of osteomyelitis at the time of Screening and Baseline Visits

10. Patient has active malignancy other than non-melanoma skin cancer

11. Patient's Index Ulcer has decreased by ≥ 30% between Screening Visit 1 and the Baseline Visit during the screening period

12. Patient has untreated alcohol or substance abuse at the time of Screening Visit 1

13. Pregnant women and women who are breastfeeding

14. Patient is currently enrolled in or has participated in another investigational device, drug, or biological trial within 30 days prior to Screening Visit 1

15. Patient has had within 14 days of Screening Visit 1, or is currently undergoing, or is planning for ulcer treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies

16. Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study

17. Patients who have already been randomized in Protocol 360 at any center may not be considered for screening or for re-entry into the trial at any center, even after the End of Treatment Study Visit

18. Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Osiris Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jaideep Banerjee, PHD

Role: STUDY_CHAIR

Smith & Nephew, Inc.

Locations

Integral Clinical Trial Solutions

Doral, Florida, United States

SSH

Weymouth, Massachusetts, United States

Countries

United States

References

Dhillon Y, Levine L, Tovmassian G, Reyzelman A, Perez-Clavijo F, Wodie F, Cazzell S, Grossman A, Robinson L, Sigal F, Kirsner RS, Vartivarian M, Saunders M, Banerjee J. A Multicenter, Randomized, Controlled, Clinical Trial Evaluating a Lyopreserved Amniotic Membrane in the Treatment of Venous Leg Ulcers. Health Sci Rep. 2025 May 4;8(5):e70819. doi: 10.1002/hsr2.70819. eCollection 2025 May.

Reference Type: DERIVED

PMID: 40330756 (View on PubMed)

Other Identifiers

Osiris Protocol 360

Identifier Type: -

Identifier Source: org_study_id

NCT03543007

Identifier Type: -

Identifier Source: nct_alias